Literature DB >> 20185590

ADAMTS13 testing: why bother?

X Long Zheng1.   

Abstract

Entities:  

Year:  2010        PMID： 20185590     DOI： 10.1182/blood-2010-01-262709

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

Review 1.  ADAMTS proteases: key roles in atherosclerosis?

Authors:  Rebecca C Salter; Tim G Ashlin; Alvin P L Kwan; Dipak P Ramji
Journal:  J Mol Med (Berl)       Date:  2010-07-22       Impact factor: 4.599

2.  Current status in diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura.

Authors:  Hayley A Hanby; X Long Zheng
Journal:  Hereditary Genet       Date:  2014

3.  Expression of ADAMTS-2, -3, -13, and -14 in culprit coronary lesions in patients with acute myocardial infarction or stable angina.

Authors:  Cheol Whan Lee; Ilseon Hwang; Chan-Sik Park; Hyangsin Lee; Duk-Woo Park; Su-Jin Kang; Seung-Whan Lee; Young-Hak Kim; Seong-Wook Park; Seung-Jung Park
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

4.  A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura.

Authors:  Yue Han; Juan Xiao; Erica Falls; X Long Zheng
Journal:  Transfusion       Date:  2011-01-20       Impact factor: 3.157

5.  Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.

Authors:  D Li; J Xiao; M Paessler; X L Zheng
Journal:  Thromb Haemost       Date:  2011-09-08       Impact factor: 5.249

6.  ADAMTS13, TTP and Beyond.

Authors:  X Long Zheng
Journal:  Hereditary Genet       Date:  2013
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.